Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 233,434,861 papers from all fields of science
Search
Sign In
Create Free Account
NE 100
Known as:
NE-100
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
TMEM 97 and PGRMC 1 do not mediate sigma-2 ligand-induced cell death
C. Zeng
,
Chi-Chang Weng
,
+7 authors
R. Mach
2019
Corpus ID: 150383064
Sigma-2 receptors have been implicated in both tumor proliferation and neurodegenerative diseases. Recently the sigma-2 receptor…
Expand
2017
2017
Issues in the Development of Multilingual Children ’ s Literacy and Literature in South Africa – Taking Stock
Semi-Annual Report
,
Ngelixa ihagu
2017
Corpus ID: 173172365
Ingqimba yeenkwenkwezi ezikude kakhulu ezibonakala njengamafu iHelix Nebula yingqimba yeenkwenkwezi zeeplanethi (iseti yamakhoba…
Expand
2013
2013
Involvement of sigma 1 receptor in the SSRI-induced suppression of the methamphetamine-induced behavioral sensitization and rewarding effects in mice.
Mahardian Rahmadi
,
T. Mori
,
Megumi Kanazawa
,
H. Kubota
,
M. Shibasaki
,
Tsutomu Suzuki
Nihon shinkei seishin yakurigaku zasshi…
2013
Corpus ID: 23315947
The abuse of methamphetamine causes abnormal behaviors which are indistinguishable from schizophrenia in humans. Recent reports…
Expand
2000
2000
Ca 2 1 Signaling via s 1 -Receptors: Novel Regulatory Mechanism Affecting Intracellular Ca 2 1 Concentration 1
Teruo Hayashi
,
T. Maurice
,
SU TSUNG-PING
2000
Corpus ID: 21966743
The s 1 -receptor is a one-transmembrane endoplasmic reticulum protein that binds neurosteroids and dextrorotatory benzomorphans…
Expand
1998
1998
抗体を機能性器材として用いる精神分裂病治療薬 NE-100 及び代謝物の高選択的分析法の開発
神宮 茂司
,
山口 順一
,
+6 authors
後藤 順一
1998
Corpus ID: 173703905
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE